Olema Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of next-generation targeted therapies for women’s cancers. Its lead product candidate, OP-1250, is a novel oral therapy with combined activity as both a complete ER antagonist. The company is also evaluating OP-1250, an estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD) in collaboration with Pfizer and Novartis for HER2- metastatic breast cancer.

Olema Oncology

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.

Olema Pharmaceuticals, Inc.

Olema Oncology is a biopharmaceutical company developing innovative targeted therapies for women’s cancers.  Our lead program, OP-1250, a potential best-in-class complete estrogen receptor antagonist (CERAN), is in development to treat estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Olema recently initiated a Phase 1/2 dose-escalation and expansion clinical trial of OP-1250. We are supported in our mission by experienced and accomplished scientists and board members, leading healthcare investors and some of the most innovative pharma companies. For more information about the company please visit www.olema.com.

Note: Olema will not conduct interviews via text message or messaging platforms and will not ask you to download anything as part of your interview.  Though we use third party tools to help with advertising our jobs, please be vigilant in checking that the communication is in fact coming from Olema.

Welcome to our newest team members, Emma Curran and Liza Bakunina MD, MS! We're excited to have you join Olema, where we're dedicated to transforming the lives of women with cancer. Together, we're #OntoSomethingBigTogether.

Learn more about opportunities at Olema today: https://bit.ly/46oWjdm

Make a meaningful difference for women battling #cancer. Join us on our mission to transform the standard of care for women with cancer. Apply today: https://bit.ly/46oWjdm

#OntoSomethingBigTogether #ClinicalScience #BioTechJobs #CMC #ClinicalSupplyChain #WomensOncology #Oncology #ClinicalDevelopment

And the list goes on! Every day, we find inspiration in the impact of our work and the commitment to scientific advancements.

Make a difference with Olema. Apply today: https://bit.ly/46oWjdm #OntoSomethingBigTogether #Oncology #WomensOncology #Biotech

Today, we honor the legacy of Dr. Martin Luther King Jr., a beacon of hope, justice, and equality. Let us carry his legacy forward, standing united for a better tomorrow. #OntoSomethingBigTogether #MLKDay #MartinLutherKing #Equality

Please welcome our new Senior Medical Director, Elisabeth de Kermadec, MD, MPH! Elisabeth is very excited to join Olema to be able to focus on her professional interest in breast cancer and develop treatments that can improve the lives of patients living with breast cancer.

Elisabeth is a medical gynecologist specializing in #BreastCancer. Elisabeth obtained her medical degree from the Paris V Descartes University in France and her MPH degree from Paris Sud University, France. She did postdoctoral training at the Dana-Farber Cancer Institute in Boston, where she explored fertility issues in young women with breast cancer. #OntoSomethingBigTogether #BreastCancerResearch

COM:OLEMA

Olema Pharmaceuticals Inc (Olema Oncology)

Last Close

14.69

26/07 17:58

Market Cap

649.39M

Beta: -

Volume Today

288.96K

Avg: -

locale

market

industry

website

crunchbase

linkedin

ipo date

peer of

Metrics